Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasatinib with Chemotherapy for High Risk AML
NCT01876953Phase 2Terminated
- Sponsor
- City of Hope
- Start
- Sep 2013
- Primary completion
- Apr 2018
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of dasatinib in acute myeloid leukemia (AML), sponsored by City of Hope. Started Sep 2013; status: terminated.
02
Drugs
dasatinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT01876953.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01876953.